The monitoring of the minimal residual disease by Wilms' tumor 1 expression (MRD WT1 ) is a standardized test, which can be used in over 80% of patients with AML. 
INTRODUCTION
Relapse following allogeneic stem cell transplantation (allo-SCT) remains the main cause of treatment failure in patients with AML. Monitoring of minimal residual disease (MRD) could allow an early detection of relapse and may be used as an efficient tool to deliver subsequent risk-adapted therapy. Common targets for PCR-based MRD detection are fusion transcripts and somatic mutations. Unfortunately, a specific marker is available only in 40-50% of AML patients. 1, 2 The Wilms' tumor 1 (WT1) gene is reportedly overexpressed in 80-90% of patients with AML and thus could be a suitable candidate for MRD. [3] [4] [5] However, the clinical impact of MRD monitoring by WT1 (MRD WT1 ) is still controversial after allo-SCT. Indeed, WT1 expression is not specific to leukemic cells. 6 Although several reports have focused on MRD WT1 after allo-SCT, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] it remains difficult to define a simple and consensual approach in standard patient care. Further studies are needed (1) to confirm the correlation between WT1 expression and relapse, (2) to define the optimal time point to assess MRD WT1 , (3) to identify the most sensitive and specific threshold for MRD WT1 positivity and (4) to evaluate the usefulness of bone marrow (BM) assessment compared with peripheral blood (PB).
In an attempt to answer these questions, we evaluated the usefulness of MRD WT1 at 3 months by assessing it as a predictor of relapse after transplant in 139 AML patients referred to our unit for allo-SCT.
PATIENTS AND METHODS
The study was approved by the independent protection committee of the North-West of France and conducted according to the Declaration of Helsinki.
Patient selection
Between January 2005 and May 2014, 201 patients with AML were referred to the University Hospital of Lille for allo-SCT. Thirty-three patients (16.4%) were excluded because WT1 was not overexpressed at diagnosis. As the objective of this study was to evaluate the impact of MRD WT1 at 3 months after allo-SCT, we further excluded 15 patients who died before the assessment date and 14 patients with missing data. Patients who relapsed before the assessment date were included in the analysis.
Patient and donor initial characteristics at diagnosis and transplantation modalities are summarized in Table 1 . The cytogenetic classification was assessed at diagnosis 19 and the cytogenetic risk was evaluated according to European LeukemiaNet (ELN) recommendations. 2 All patients were treated on Institutional Review Board-approved protocols. 20 
Chimerism
Chimerism was assessed at 3 months post transplant by quantitative realtime PCR based on short insertion/deletion polymorphisms using TaqMan probes, with a sensitivity of 0.2%. Chimerism assays were performed on sorted T cells from PB with magnetic beads. Full and mixed donor chimerism were defined by the presence of at least 95% and between 6% and 94% of CD3+ donor T cells, respectively.
Statistical analyses
The primary end point was the cumulative incidence of relapse. The secondary end points included 3-year event-free survival (EFS), overall survival (OS) and comparison between MRD WT1 and chimerism. Acute and chronic GvHDs were diagnosed according to the standard criteria. 23, 24 Analysis of EFS and OS was performed using the Kaplan-Meier method, with differences compared using the log-rank test. Cumulative incidence was estimated using a competitive-risk approach. All variables having a significance level of P o 0.10 in the bivariate analyses were introduced in a multivariable Fine and Gray model, 25 with backward selection. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were computed and P ⩽ 0.05 was considered statistically significant. All analyses were performed using the SAS software (SAS Institute Inc., Cary, NC, USA).
RESULTS
The median follow-up was 39.3 (6.4-99.8) months and 3-year OS, EFS, relapse and non-relapse mortality rates were 63.4%, 62.6%, 30.2% and 9.4%, respectively. Thirty-six (25.9%) patients developed acute grade II-IV GVHD and 45 (32.4%) chronic GVHD.
WT1 expression 3 months post transplant MRD
WT1 was positive at 3 months after allo-SCT in 30 patients. There was no significant difference in terms of age, gender, molecular finding, genetic risk, source of stem cell, use of antithymocyte globulin or incidence of GVHD between patient with positive and negative MRD WT1 (Table 1) . Although progressive disease (P = 0.03) and reduced intensity conditioning (P = 0.046) seemed associated with positive MRD WT1 in univariate analysis, only unfavorable karyotype (HR: 2.7; 95% CI: 1.10-6.63; P = 0.0301) was a significant factor in multivariate analysis.
Patient outcomes associated with WT1 expression The cumulative incidence of relapse was 90% in MRD WT1 -positive patients (27/30) compared with 14.7% in MRD WT1 -negative patients (16/109) (P o0.0001) (Figure 1a) . Relapse occurred later than 1 and 3 months after MRD WT1 test in 50% and 33% of cases, respectively (median 31 days, interquartile range Correlation between WT1 expression in PB and BM The correlation between relapse and MRD WT1 was stronger in PB than in BM (Pearson's correlation coefficient of 0.584 and 0.613, respectively). Similar results in terms of relapse and survival were observed with either PB or BM alone (Figures 2a and b) . Analyses using WT1 kinetics (decrement ratio between pre-transplant and post transplant expression) were not found to be more discriminant than the ELN criteria. Of note, the most sensitive and specific upper limits of normal in this cohort were 123 and 6.8 WT1 copies per 10 4 ABL copies in BM and PB, respectively (receiver operating curve models).
Patient outcomes associated with chimerism Chimerism at 3 months was full donor in 103/127 evaluable patients (81.1%) and mixed donor in 24 patients, among whom 13 had a loss of donor chimerism and 11 never reached full donor chimerism. Relapse occurred in 24.3% vs 45.8% of patients with 3-month full donor and mixed chimerism, respectively (P = 0.014) (Figures 3a and b) . Loss of donor chimerism was not associated with relapse (P = 0.133). In multivariate analysis, 3-month mixed chimerism was associated with a higher incidence of relapse (HR: 2.87; 95% CI: 1.48-5.52; P = 0.0017) and decreased EFS (HR: 2.39; 95% CI: 1.12-5.15; P = 0.0249) ( Table 2 ). However, considering the HR and the fit of the model (the percentages of decrease of AIC were 16.2% and 1.2% for the models with MRD and chimerism, respectively) chimerism had less impact on relapse and EFS than MRD WT1 . In contrast with MRD WT1 , 3-month chimerism had no impact on OS (68.5% vs 66.7% in patients with full donor and mixed chimerism, respectively; P = 0.45).
DISCUSSION
Findings from this study suggest that the ELN criteria for MRD monitoring by WT1 can be applied after allo-SCT to identify very poor-risk patients with AML. MRD monitoring by WT1 expression should be performed in blood samples rather than in BM. Finally, MRD WT1 positivity at 3 months post transplant was more predictive of relapse and EFS than 3-month chimerism.
Several studies have previously reported on MRD WT1 after allo-SCT. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Interpretation of their results is difficult because series were limited [7] [8] [9] [10] 12, 15, 17 and/or did not restrict the inclusion criteria to AML. 7, 8, 10, 12, 14, 16, 17 In contrast with most reports, [7] [8] [9] [10] [11] [12] 14, 15, 17, 18 we assessed MRD WT1 at a single time point, both in PB and BM. Our data demonstrate that the correlation between relapse and 3-month MRD WT1 is stronger in PB than in BM. Also, sample collection is obviously more convenient in PB than BM. Thus, we recommend monitoring WT1 expression in PB.
While previous reports used a wide variability of methods to assess MRD WT1 positivity, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] our data validate the usefulness of ELN criteria after allo-SCT to identify very poor-risk patients. In addition, strength of our study is to be non-interventional. Indeed, MRD WT1 positivity did not lead to any therapeutic decision in order to prevent relapse. In contrast with others, [10] [11] [12] 14, 16, 18 our findings Variables having a significance level of P40.10 in the univariate analyses.
WT1 monitoring after allo-SCT in AML R Duléry et al were therefore not confounded by early immunosuppressive therapy discontinuation or donor lymphocyte injection based on MRD WT1 results. Chimerism is commonly used in allo-SCT to predict relapse. 26 In line with previous studies, 8, 9, 12, 26 mixed chimerism at 3 months was associated with a higher risk of relapse and decreased EFS. However, 3-month chimerism did not influence OS and had significantly less impact on relapse and EFS than MRD WT1 . Overall, MRD WT1 monitoring in PB appeared to be a more relevant biomarker than chimerism to identify poor-risk AML patients after allo-SCT.
Relapse occurred within 1 month after MRD WT1 testing in 50% of cases. This raises the question of monitoring MRD WT1 earlier than 3 months after allo-SCT to anticipate the risk-adapted therapy in those patients. However, there could be two limitations to an earlier strategy. First, immunosuppressive withdrawal, donor lymphocyte injection and/or chemotherapy administration may be a difficult approach within the 3 first months post transplant because of a higher risk of toxicity and development of GVHD. Second, one must be cautious with WT1 expression kinetics after allo-SCT. In patients with positive MRD WT1 before allo-SCT, WT1 may remain overexpressed at 1 or 2 months post transplant and decrease progressively until reaching negativity at 3 months. In our study, MRD WT1 was not monitored in all patients before 3 months. Among the 41 patients with positive MRD WT1 before allo-SCT, 25 had negative MRD WT1 at 3 months post transplant. Among the 26 patients assessed at 2 months, 2 MRD WT1 -positive patients became MRD WT1 negative at 3 months and did not relapse. Therefore, prospective studies with systematic MRD WT1 monitoring at 1 and 2 months post transplant are needed.
In conclusion, MRD WT1 monitoring can be performed in over 80% of AML patients undergoing allo-SCT. Using the ELN criteria, WT1 overexpression in PB is highly predictive of post-transplant relapse. Therefore, quantification of WT1 expression should be performed in PB after allo-SCT to identify very poor-risk patients, who could benefit from early immunosuppressive therapy discontinuation, preemptive donor lymphocyte injection 
